(PharmaNewsWire.Com, May 26, 2020 ) Growth in the primary cells market is mainly driven by factors such as increasing cancer research; the advantages of primary human cells over cell lines; the increasing demand for monoclonal antibodies; rapid growth in the biotechnology and biopharmaceutical industries, partnerships, collaborations, and acquisitions; and increasing pharmaceutical outsourcing.
The primary cells market is expected to reach USD 1,107.3 million by 2023 from USD 666.0 million in 2017 at a CAGR of 8.5% from 2018–2023. The base year for this study is 2017 and the forecast period is 2018–2023.
The global primary cells market is segmented by origin, type, end user, and region. By origin, the primary cells market is classified into hematopoietic, skin, gastrointestinal, liver, lung, renal, heart, skeletal & muscle, and other primary cells. The liver cells segment is expected to register the highest CAGR during the forecast period due to their increasing demand in toxicological and pharmacological studies.
Based on type, the market is segmented into human and animal primary cells. The human primary cells segment is expected to register the highest CAGR during the forecast period owing to the high adoption of human primary cells in the development of novel cancer therapies. Human primary cells are also extensively used for studying human cancerous cell models, in toxicology studies, and in the cosmetic industry.
The global primary cells market is dominated by North America, followed by Europe. North America will continue to dominate the global primary cells market during the forecast period, however, Asia is expected to witness the highest CAGR, with the growth in this market centered on China and Japan. Increasing number of players launching new human primary cells for research, expansion of pharmaceutical and biotechnology industries, and increasing prevalence of cancer in the region are the major factors driving the growth of the North American market.
Key Market Players
The major players in this market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (US), PromoCell (Germany), ZenBio (US), STEMCELL Technologies (Canada), AllCells (US), American Type Culture Collection (US), and Axol Biosciences (UK).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
